Search results
Results from the WOW.Com Content Network
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) breast cancer with positive HER2/neu receptor Thal/Dex thalidomide, dexamethasone: multiple myeloma: TIP paclitaxel (Taxol), ifosfamide, platinum agent ...
In the United States, trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. [11] It is administered by intravenous injection. [11] There is also an albumin-bound formulation. [11]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Simple blood tests are also available for dose optimization of methotrexate, [32] 5-FU, paclitaxel, and docetaxel. [ 33 ] [ 34 ] The serum albumin level immediately prior to chemotherapy administration is an independent prognostic predictor of survival in various cancer types.
By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines.
In breast cancer, adjuvant therapy may consist of chemotherapy (doxorubicin, trastuzumab, paclitaxel, docetaxel, cyclophosphamide, fluorouracil, and methotrexate) and radiotherapy, especially after lumpectomy, and hormonal therapy (tamoxifen, letrozole).